Genetic Testing Services
Customize your policy alerts
Sign up for all Blue Cross Blue Shield - Rhode Island policy alerts
Know when Blue Cross Blue Shield - Rhode Island releases new policies or updates existing guidance.
Monitor payer policy activity
Policy governing medical necessity, coverage, and prior authorization requirements for genetic and molecular testing services for BCBSRI members (Medicare Advantage and Commercial products). Applies to ordering providers and laboratories interacting with BCBSRI.
No material clinical or coverage changes in this revision.
Coverage and Medical Necessity Criteria
Medical Necessity Criteria
Covered when ALL of the following are met (per category or specific online criteria):
First- and second-degree relatives defined in policy (first-degree: biological parent, brother, sister, or child; second-degree: grandparent, aunt/uncle, niece/nephew, grandchild, half‑sibling).
Applied via online authorization tool/InterQual where specific criteria sets exist.
Context-specific criteria applied via the online authorization tool.
Not Medically Necessary when Evidence Insufficient
General limitations and coverage stance
Policy identifies multiple tests with extremely limited published data or insufficient evidence demonstrating clinical validity as not medically necessary.
Tests considered not medically necessary or not covered include those with insufficient clinical evidence or limited published data demonstrating clinical validity or utility. When evidence does not support that a test will meaningfully inform patient management or improve health outcomes, the service may be denied as not medically necessary or not covered. Whole panels may be considered not covered when component genes or variants within the panel lack demonstrated clinical usefulness.
Genetic tests that lack demonstrated clinical utility or do not have sufficient evidence of clinical validity are excluded from coverage as not medically necessary. The policy specifically identifies tests where published data are extremely limited or where validity has not been established as examples that will be excluded from medical necessity coverage.
For both Medicare Advantage and Commercial products, when prior authorization is indicated coverage is contingent on meeting the online authorization criteria and policy requirements. Genetic testing services are not covered for Medicare Advantage Plans and are considered not medically necessary for Commercial Products when there is insufficient clinical evidence, results would not reasonably be used in patient management, or the service is unlikely to affect therapeutic decision-making.
The policy notes that there are several specific tests with extremely limited published data and insufficient evidence of clinical validity; such tests are considered to have inadequate evidence to determine impact on health outcomes and are therefore not medically necessary.
Covered Indications for Genetic Testing
Carrier Screening — Covered Indications
First- and second-degree relative definitions provided in policy.
Referenced as requirement for carrier screening in the online authorization criteria.
Population carrier-rate thresholds are applied as appropriate for specific conditions per authorization criteria.
Diagnostic Testing — Covered Indications
Use InterQual/online authorization criteria for condition-specific application.
Applied where testing will benefit the individual by informing diagnosis or management.
Cancer-Related Genetic Testing — Covered Indications
Applied per online criteria for cancer-related testing.
Therapeutic, somatic testing is intended to benefit the individual by guiding targeted treatment decisions.
Eligibility and Patient Selection
Coverage for carrier screening requires documented family- or population-based risk: one or both individuals must have a first- or second-degree relative who is affected, or one individual is a known carrier, or one or both individuals are from a population with an elevated carrier rate; additionally, previous carrier screening or targeted testing for the variant(s) of interest must not have been performed prior to coverage.
Additional eligibility requirements and decision nodes are applied in the online authorization tool and depend on the category of testing; refer to the BCBSRI authorization criteria for condition- and test-specific eligibility details.
Other eligibility considerations (for example, prior testing performed, symptomatic status, or diagnostic intent) are evaluated through the authorization workflow and associated criteria; providers should use the online prior authorization tool and the linked code/coverage grid for precise guidance.
Provider Actions, Prior Authorization, and Documentation
Prior Authorization Required
Prior authorization is required for Medicare Advantage plans and recommended for Commercial Products. Submit authorization requests via the BCBSRI online prior authorization tool (available to BCBSRI-participating providers). Providers who are not BCBSRI-participating may fax requests to Utilization Management at (401) 272-8885. If a genetic test is not found in the online authorization tool, fax the request to Utilization Management at (401) 272-8885. Panel testing: prior authorization is required for each component and/or gene/gene variant of panel testing when the panel is represented by multiple CPT codes; each individual CPT code must be entered into and processed through the online authorization tool independently. Effective 10/1/2025, for Fully-Funded Commercial Products only, prior authorization requests may not be needed when the requesting physician is a BCBSRI contracted Primary Care Provider (Internal Medicine, Pediatric Medicine, Family Practice, Obstetrics and Gynecology, Doctor of Osteopathic Medicine, NP/PCP, PA).
- Submit authorizations via BCBSRI online prior authorization tool
- Fax for non-participating providers or tests not in the tool: (401) 272-8885
- Panel testing: enter each CPT component separately
- PCP exemption for Fully-Funded Commercial Products effective 10/1/2025
Submission and Documentation Requirements
Submit required clinical documentation with authorization requests to demonstrate medical necessity as specified in the online authorization tool criteria. Provide supporting clinical information that links the requested test to the patient’s signs, symptoms, family history, diagnosis codes, and prior testing where applicable. Only the ordering physician may participate in the authorization, appeal, or other administrative processes related to prior authorization/medical necessity; laboratories or third parties are not permitted to obtain authorization on behalf of the ordering physician.
- Include clinical rationale, relevant diagnosis codes, prior test results, and family history as applicable
- Only the ordering physician may submit or pursue authorizations/appeals — labs/third parties may not act on the provider’s behalf
Check Coding/Authorization Grid
Coverage, medical necessity, and whether prior authorization is required vary by code, indication, and product. Providers should consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet to determine which CPT/PLA codes and indications require authorization or are covered, medically necessary, not medically necessary, or not covered.
- See: Genetic Testing Codes and Coverage Effective 6/1/2026 spreadsheet
- Use the spreadsheet to identify codes/indications requiring prior authorization and appropriate diagnosis coding
Tests with Insufficient Evidence — Denial Risk
There are several tests and genetic panels with insufficient published evidence of clinical validity or clinical utility. Tests lacking sufficient evidence are considered not medically necessary and are at high risk for denial. Prior authorization and supporting documentation should demonstrate clinical validity and expected impact on patient management to reduce denial risk.
- Tests/panels with insufficient evidence may be denied as not medically necessary
- Document how results will influence clinical management to support medical necessity
Consult the BCBSRI Genetic Testing Codes and Coverage Spreadsheet
Providers should consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet to determine specific codes and indications that require authorization and to review coverage status or related policy references. The code grid provides guidance for diagnosis coding, PLA/MAAA rules, and per-code coverage determinations.
- Reference the downloadable code grid for per-code coverage and comments
- Follow related policy links referenced in the grid for tests governed by other BCBSRI policies
Step Therapy / Sequencing Guidance
No specific step therapy sequencing guidance is provided within this policy section. For sequencing, prior authorization requirements, and coverage order of tests, consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet and related policies referenced therein.
- Follow the external coding/coverage grid for sequencing or step requirements
Ordering Physician Responsibility
Ordering physician must be the individual to submit and pursue authorizations and appeals. Rules differ for Fully-Funded Commercial Products where select BCBSRI-credentialed primary care specialties may be exempt from prior authorization requirements per the PCP exemption effective 10/1/2025.
- Only the ordering physician may be involved in authorization/appeal processes
- PCP exemption applies to listed specialties for Fully-Funded Commercial Products beginning 10/1/2025
Genetic Testing Codes and Coverage
| See attached grid | Genetic Testing Codes and Coverage Effective 6/1/2026 spreadsheet (external link) |
| see spreadsheet | Genetic testing CPT/HCPCS codes and coverage determinations are listed in the linked Genetic Testing Codes and Coverage spreadsheet effective 6/1/2026. |
Refer to external code/authorization grid for code‑level rules
Refer to the external Genetic Testing Codes and Coverage spreadsheet for code‑level authorization, coverage, and documentation rules — this policy defers code‑specific determinations to the linked grid.
- The attached spreadsheet provides code‑level indications of coverage and authorization requirements effective 6/1/2026.
- Use the grid for the most up‑to‑date code‑specific rules.
Check the Genetic Testing Codes & Coverage spreadsheet to confirm authorization and documentation needs by code
Providers must consult the BCBSRI Genetic Testing Codes and Coverage spreadsheet (linked in the policy) to determine which CPT codes and clinical indications require prior authorization and what documentation is required to meet medical necessity.
- The spreadsheet identifies codes that may be covered, medically necessary if criteria met, not medically necessary, or not covered.
- For panel tests filed with specific individual CPT codes, refer to the grid and related policies (eg, PLA and MAAA) for coverage guidance.
Tests Not Covered / Not Medically Necessary
Genetic panels or individual tests that lack sufficient clinical evidence or clinical utility are listed as not covered. Panels whose component genes or variants do not have demonstrated usefulness for guiding management may be denied in their entirety for Medicare Advantage and deemed not medically necessary for Commercial Products.
Tests determined to lack clinical validity or utility based on insufficient evidence are explicitly categorized as not medically necessary. When available data are inadequate to establish that a test will affect patient outcomes or clinical decision-making, coverage will be denied.
Definitions and Test Types
Background and Rationale
Genetic tests can guide interventions in symptomatic or asymptomatic individuals by identifying causal variants, estimating future risk, informing prognosis, and directing treatment selection. Molecular pathology and genomic sequencing procedures (eg, NGS) analyze DNA/RNA to detect germline or somatic variants, and multianalyte assays/MAAAs may generate algorithmic scores; the clinical utility of these technologies is condition- and test-specific and subject to the limitations of testing methods (for example, potential to miss variants, identification of variants of uncertain significance, genetic heterogeneity, and laboratory error).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.